Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Axitinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
Glenmark has received tentative approval by the United States Food & Drug Administration (U.S. FDA) for Axitinib Tablets, 1 mg and 5 mg, the generic version of Inlyta Tablets, 1 mg and 5 mg, of PF Prism C.V.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Palbociclib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), lbrance Capsules, 75 mg, 100 mg, and 125 mg, of Pfizer Inc. (Pfizer).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Doxorubicin HCl
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2020
Details:
Zydus Cadila has received final approval from the USFDA to market Doxorubicin Hydrochloride Liposome Injection in the strengths of 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials. First approval for a complex injectable which has been developed in-house.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Trastuzumab
Therapeutic Area: Oncology Product Name: Herclon
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 17, 2020
Details:
Cipla entered a distribution agreement with Roche Products to expand scope of the partnership to include, marketing and distribution of Roche’s trademark oncology drugs - Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab (Ristova) in India.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
